September 22, 2023 03:25 PM EDTUpdated 04:02 PM
Pharma
Marketing

Ozem­pic sales surge could con­tin­ue in­to 2024, re­searchers say

Nicole DeFeudis

Editor

No­vo Nordisk’s di­a­betes treat­ment Ozem­pic could be the drug in­dus­try’s sec­ond-high­est sell­er in 2024, ac­cord­ing to Eval­u­ate’s lat­est fore­cast, as an­a­lysts and physi­cians sig­nal the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times